Administration of combined contraceptive containing dienogest and ethinyl estradiol for endometriosis

L. V. Yerofeyeva
In: Medical Council · 2016 · pp. 14–21 · doi:10.21518/2079-701x-2016-2-14-21 · W2612958566
article OA: diamond CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

A combined contraceptive with ethinylestradiol and dienogest effectively treats endometriosis by inhibiting disease progression and reducing recurrence during long-term cyclic or continuous administration.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This paper discusses the use of a combined contraceptive containing dienogest and ethinyl estradiol for the treatment of endometriosis, situating the approach within broader concepts of hormonal modulation and existing clinical recommendations. It summarizes prior evidence and guideline-based considerations regarding endometriosis management and the role of hormone therapies, including references to research on dienogest and to topics such as quality of life and pain outcomes in endometriosis. The explicit limitation is that the provided text does not include the paper’s original study design, participant data, or outcome results—only the title, bibliographic metadata, and a reference list are shown. This paper is centrally about endometriosis — it focuses on administering a combined contraceptive with dienogest and ethinyl estradiol in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The article tells about the use of a combined contraceptive preparation containing the novel progestogen - dienogest - in conservative antirecurrent treatment of endometriosis. According to current concepts, endometriosis is a chronical dishormonal, immunodependent, multifactorial, genetically determined disease which manifests itself in the growth and presence of endometrioid heterotopias in the uterus. While accurate diagnosis and ablation of heterotopias require surgery, for subsequent treatment, doctor's toolkit offers a multitude of medicines the effects of which are on the whole described by the following: fight against manifestations of endometriosis, inhibition of the progression of the process, reduction of the disease recurrence, and improving the quality of life of patients. Pharmacotherapy of endometriosis should be effective and safe. Dienogest demonstrated properties comparable to those of gonadotropin-releasing hormone agonists, especially for early clinical manifestations of endometriosis. The combined contraceptive containing ethinylestradiol and dienogest is best suited for long-term (several months) treatment of endometriosis under a cyclic or continuous regimen.
Full text 7,205 characters · extracted from oa-doi-fallback · click to expand
Применение комбинированного контрацептивного препарата, содержащего диеногест и этинилэстрадиол, при эндометриозе https://doi.org/10.21518/2079-701X-2016-2-14-21 Аннотация Об авторе Л. В. ЕрофееваРоссия Список литературы 1. Всемирная организация здравоохранения (ВОЗ) http://www.who.int/Life-course/news/ events/accountabiLity-post-2015-consuLtation/ en/, на 30 ноября 2015 г. 2. Muneyyirci-DeLaLe 0, Sinaii N, Charles C et aL. Changes in quaLity of Life (Q0L) in women with symptomatic endometriosis by pain type during treatment. Fertility and Sterility, 2010 September, 94, 4: S206. 3. Muneyyirci-DeLaLe O, CharLes C, Sinaii N et aL. HeaLth-reLated quaLity of Life improvement in women with endometriosis-associated pain during treatment. Fertility and Sterility, 2014 September, 102, 3: e14. 4. Адамян Л.В., Сонова М.М., Тихонова Е.С. и соавт. Медицинские и социальные аспекты генитального эндометриоза. Проблемы репродукции, 2011, 6: 78-81. 5. ASRM (American Society for Reproductive Medicine). The Practice Committee. Endometriosis and infertiLity: a committee opinion. Fertility and Sterility, 2012, 98: 591-598. 6. Кира Е.Ф., Цвелев Ю.В. Эндометриоидная болезнь. Гинекология: Руководство для врачей, Под ред. В.Н. Серова, Е.Ф. Кира. М.: Литера, 2008. 840 c. 7. http//www.asrm.org/FertilityAnd Sterility/, на 27 ноября 2015 г. 8. Адамян Л.В. и соавт. Эндометриоз: диагностика, лечение, реабилитация. Федеральные клинические рекомендации по ведению больных, М., 2013, 65 с. 9. Адамян Л.В., Андреева Е.Н. Роль современной гормонмодулирующей терапии в комплексном лечении генитального эндометриоза. Проблемы репродукции, 2011, 6: 66-77. 10. Унанян А.Л. Эндометриоз и репродуктивное здоровье женщин. Акушерство, гинекология и репродукция, 2010, 3, 4. 11. Кузнецова И.В. Эндометриоз: патофизиология и выбор лечебной тактики. Гинекология, 2008, 5: 74-79. 12. Логинова О.Н., Сонова М.М. Клинические особенности наружного генитального эндометриоза. Акушерство. Гинекология. Репродукция, 2011, 6: 28-29. 13. Сметник В.П. Фармакотерапия генитального эндометриоза. Consilium medicum, 2002, 4(10): 8-12. 14. Стрижаков А.Н., Давыдов А.И. Эндометриоз. Клинические и теоретические аспекты. М.: Медицина, 1996. 330 с. 15. Guo SW. Epigenetics of endometriosis. Review. Mol Hum Reprod, 2009, 15: 587-607. 16. Abou-Setta AM, AL-Inany HG, Farquhar CM. Levonor-gestreL-reLeasing intrauterine device (LNG-IUD) for symptomatic endometriosis foLLowing surgery Cochrane Database Syst Rev., 2006, 4. CD005072. 17. SeLak V, Farquhar C, Prentice A et aL. DanazoL for peLvic pain associated with endometriosis. Cochrane Database Syst Rev., 2001, 4. CD000068. 18. MitwaLLy MF, GotLieb L, Casper RF. Prevention of bone Loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in Long-term GnRH-agonist down-reguLated patients with endometriosis and premenstruaL syndrome. Menopause, 2002, 9: 236-241. 19. Stefano Luisi, GabrieLe Centini, Lucia Lazzeri Current approach to treatment of pain in patients with endometriosis: resuLts of a survey of speciaLists in ItaLy. Journal of Endometriosis, 2015, 7(1): 49-50. 20. ALLen C, HopeweLL S, Prentice A et aL. Non-steroidaL anti-infLammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev, 2005, 4. CD004753. 21. American Psychiatric Association. Practice GuideLine for the Treatment of Psychiatric Disorders, Compodium. - ArLington, Va: American Psychiatric PubLishing, Inc. 2006. 22. Tasuku Harada, Mikio Momoeda, Yuji Taketani, et aL. Dienogest is as effective as intranasaL busereLin acetate for the reLief of pain symptoms associated with endometriosis -- a randomized, doubLe-bLind, muLticenter, controLLed triaL. Fertility and Sterility, 2009, 91(3): 675-681. 23. Cosson M, QuerLeu D, Donnez J et aL. Dienogest is as effective as triptoreLin in the treatment of endometriosis after Laparoscopic surgery: ResuLts of a prospective, muLticenter, randomized study. Fertil Steril, 2002, 77, 4: 684-692. 24. Strowitzki T, Marr J, GerLinger C et aL. Dienogest is as effective as LeuproLide acetate in treating the painfuL symptoms of endometriosis: a 24-week, randomized, muLticentre, open-LabeL triaL. Hum Reprod., 2010, 25: 633-641. 25. Momoeda M, Taketani Y. Randomized doubLe-bLind, muLticentre, paraLLeL-group dose-response study of dienogest in patients with endometrio-sis. Jpn Pharmacol Ther., 2007, 35: 769-783. 26. Katsuki Y, Takano Y, Futamura Y et aL. Effects of dienogest, a synthetic steroid, on experimentaL endometriosis in rats. Eur J Endocrinol., 1998, 138: 216-226. 27. Yoshiaki Ota, Masaaki Andou, Shiori Yanai, et aL. Long-term administration of dienogest reduces recurrence after excision of endometrioma. Journal of Endometriosis, 2015, 7(2): 63-67. 28. Haider Z, D'Souza R. Non-contraceptive benefits and risk of contraception. Best Pract Res Clin Obstet Gynecol., 2009, 23: 249-262. 29. The World Health Organization (WHO)http://www.who.int/life-course/news/events/accountability-post-2015-consultation/en/, November 30, 2015 30. Kira E.F., Tsvelev Y.V. Endometrial disease. Gynecology: guide for physicians, ed. by V.N. Serov, E.F. Kira. М.: Litera, 2008. 840 p. 31. http://www.asrm.org/FertilityAndSterility/, November 27, 2015. 32. Adamyan L.V. et al. "Endometriosis diagnosis, treatment, rehabilitation", Federal clinical guidelines for the management of patients, M. 2013, 65 p. 33. Adamyan L.V., Andreeva E.N. The role of present-day hormone modulation therapy in the treatment of endometriosis. Problemy Reproduktsii, 2011, 6: 66-77. 34. Unanyan A.L. Endometriosis and women's reproductive health. Akusherstvo, Ginekologiya i Reproduktsiya, 2010, 3, 4. 35. Kuznetsova I.V. Endometriosis: pathophysiology and choice of treatment tactics. Ginekologiya, 2008, 5: 74-79. 36. Loginova O.N., Sonova M.M. Clinical features of external genital endometriosis. Akusherstvo. Ginekologiya. Reproduktsiya, 2011, 6: 28-29. 37. Smetnik V.P. Pharmacotherapy of genital endometriosis. Consilium medicum, 2002, 4(10): 8-12. 38. Strizhakov A.N., Davydov A.I. Endometriosis. Clinical and therapeutic aspects. М.: Meditsina, 1996. 330 p. 39. Tikhomirov A.L., Oleinik C.G. Options for prolonged use of combined oral contraceptives. Ginekologiya, 2007, 9, 3: 28-30. 40. Khamoshina M.B., Sorokina A.V., Vakhabova M.I., Kalinina E.A. Management of patients with endometriosis from the standpoint of global and national clinical guidelines. Status Praesens, 2014, 2(19): 53-58. 41. Tikhomirov A.L. Endometriosis is a purely surgical pathology? Ginekologiya, Vol.15, №2, p. 74-77 42. Korennaya V.V., Kayikhabanova K.N., Lyubimova E.A., Agisheva V.V. Prolonged regimens of combined hormonal contraceptives. Ginekologiya, 2015, 17(3): 23-25. Рецензия Для цитирования: Ерофеева ЛВ. Применение комбинированного контрацептивного препарата, содержащего диеногест и этинилэстрадиол, при эндометриозе. Медицинский Совет. 2016;(2):14-21. https://doi.org/10.21518/2079-701X-2016-2-14-21 For citation: Yerofeyeva LV. Administration of combined contraceptive containing dienogest and ethinyl estradiol for endometriosis. Meditsinskiy sovet = Medical Council. 2016;(2):14-21. (In Russ.) https://doi.org/10.21518/2079-701X-2016-2-14-21 JATS XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK